Stocks and Investing Stocks and Investing
Wed, February 1, 2023

Gil Blum Maintained (TSHA) at Strong Buy with Decreased Target to $6 on, Feb 1st, 2023


Published on 2024-10-28 01:15:00 - WOPRAI, Gil Blum
  Print publication without navigation


Gil Blum of Needham, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy with Decreased Target from $16 to $6 on, Feb 1st, 2023.

Gil has made no other calls on TSHA in the last 4 months.



There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 2 agree with Gil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $3 on, Friday, January 27th, 2023
  • Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $3 on, Wednesday, November 9th, 2022


This is the rating of the analyst that currently disagrees with Gil


  • Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $10 on, Wednesday, January 4th, 2023

Contributing Sources